← 返回

我如何诊断 EBV 阳性 B 细胞及 T 细胞淋巴增殖性疾病

英文原题:How I Diagnose EBV-Positive B- and T-Cell Lymphoproliferative Disorders.

查看英文原题

How I Diagnose EBV-Positive B- and T-Cell Lymphoproliferative Disorders.

PubMed 2023/01/04(内容时间) Am J Clin Pathol Q2 · IF 2.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

对 EBV 相关 LPD 的更深入理解,促成了对 B 细胞、T 细胞和 NK 细胞来源的明确疾病实体的认识,并因此改善了其以治愈为目的的治疗。

中文摘要

EB病毒(EBV)相关淋巴增殖性疾病(LPD)包括一组来源于B细胞、T细胞和自然杀伤(NK)细胞的明确疾病实体。由于其临床和形态学表现可能与其他良性或恶性EBV阳性淋巴增殖性疾病重叠,诊断颇具挑战。本文介绍我们对EBV相关LPD的诊断方法。

通过两个病例说明诊断过程。第一例为儿童系统性EBV阳性T细胞淋巴瘤,第二例为EBV阳性黏膜皮肤溃疡。文章重点强调有助于将这些疾病与生物学或形态学相似病变相鉴别的临床病理特征。

准确诊断EBV相关LPD需要综合组织学和免疫表型特征、评估EBV潜伏感染程序,最重要的是结合完整临床资料。克隆性分析无助于区分良性与恶性EBV阳性LPD。

随着对EBV相关LPD认识的加深,B细胞、T细胞和NK细胞来源的多种明确疾病实体得以识别,其根治性治疗也因此得到改善。准确区分良性和恶性EBV阳性LPD至关重要,可避免过度治疗。

展开英文摘要原文

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders (LPDs) encompass a group of well-defined entities of B-, T-, and natural killer (NK)-cell derivation. The diagnosis of these disorders is challenging because of clinical and morphologic features that may overlap with other benign and malignant EBV+ lymphoproliferations. This review describes our approach to the diagnosis of EBV-associated LPDs.

Two cases are presented that illustrate how we diagnose EBV-associated LPDs. The first case represents a systemic EBV+ T-cell lymphoma of childhood and the second case an EBV+ mucocutaneous ulcer. The clinicopathologic features that help distinguish these entities from biological and morphologic mimickers are emphasized.

The accurate diagnosis of EBV-associated LPDs requires the incorporation of histologic and immunophenotypic features, the assessment of the EBV latency program, and, most important, complete clinical findings. Clonality analysis is not helpful in distinguishing benign from malignant EBV+ LPDs.

The better understanding of EBV-associated LPDs has resulted in the recognition of well-defined entities of B-, T-, and NK-cell derivation and consequently improvement of their treatment with curative intent. It is critical to distinguish benign from malignant EBV+ LPDs to avoid overtreatment.

论文信息

作者
Dojcinov SD、Quintanilla-Martinez L
第一作者单位
All Wales Lymphoma Panel, Swansea Bay University Health Board and Swansea University, Swansea, Wales.United Kingdom
通讯作者单位
Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany.Germany
文献类型
综述
期刊
American journal of clinical pathology2023 Jan 4
原文标识
PubMed 36214507 · DOI 10.1093/ajcp/aqac105